bupropion has been researched along with Anxiety in 34 studies
Bupropion: A propiophenone-derived antidepressant and antismoking agent that inhibits the uptake of DOPAMINE.
bupropion : An aromatic ketone that is propiophenone carrying a tert-butylamino group at position 2 and a chloro substituent at position 3 on the phenyl ring.
Anxiety: Feelings or emotions of dread, apprehension, and impending disaster but not disabling as with ANXIETY DISORDERS.
| Excerpt | Relevance | Reference |
|---|---|---|
| " This study explored whether anxiety predicts suicidal ideation in depressed individuals treated with paroxetine or bupropion." | 9.27 | Effects of anxiety on suicidal ideation: exploratory analysis of a paroxetine versus bupropion randomized trial. ( Burke, AK; Chaudhury, SR; Ellis, SP; Grunebaum, MF; Keilp, JG; Mann, JJ; Marver, JE; Metts, AV; Oquendo, MA; Parris, MS, 2018) |
| "We tested the efficacy of bupropion in the treatment of persons with pathological gambling (PG)." | 9.12 | Bupropion in the treatment of pathological gambling: a randomized, double-blind, placebo-controlled, flexible-dose study. ( Allen, J; Argo, T; Arndt, S; Black, DW; Coryell, WH; Forbush, KT; Perry, P; Shaw, MC, 2007) |
| "Our objective was to determine if pretreatment anxiety levels were associated with preferential response to bupropion sustained release (n = 122) or sertraline (n = 126) during a 16-week randomized acute phase treatment study." | 9.09 | Response in relation to baseline anxiety levels in major depressive disorder treated with bupropion sustained release or sertraline. ( Ascher, JA; Batey, SR; Bolden-Watson, C; Carmody, TJ; Donahue, RM; Houser, TL; Metz, A; Rush, AJ; Trivedi, MH, 2001) |
| "The goal of this work was to compare the efficacy of the norepinephrine-dopamine reuptake inhibitor bupropion with the selective serotonin reuptake inhibitors (SSRIs) in the treatment of anxiety symptoms in major depressive disorder (MDD)." | 8.84 | Efficacy of bupropion and the selective serotonin reuptake inhibitors in the treatment of anxiety symptoms in major depressive disorder: a meta-analysis of individual patient data from 10 double-blind, randomized clinical trials. ( Alpert, JE; Goodale, EP; Krishen, A; Papakostas, GI; Seifert, CA; Trivedi, MH; Tucker, VL, 2008) |
| "The aim of this study was to assess the effects of the antidepressant bupropion on anxiety and novelty-seeking in adolescent mice of different ages and adults." | 7.79 | Bupropion induced changes in exploratory and anxiety-like behaviour in NMRI male mice depends on the age. ( Carrasco, MC; Redolat, R; Vidal, J, 2013) |
| "Evaluate acute effects of bupropion on locomotor activity, isolation-induced aggression, hole-board and elevated plus-maze tests in OF1 male mice." | 7.73 | Bupropion effects on aggressiveness and anxiety in OF1 male mice. ( Carrasco, MC; Gómez, MC; Redolat, R; Vicens, P, 2005) |
| "To assess if certain personality factors (anxiety or depression) might predict the efficacy of bupropion for smoking cessation." | 7.71 | [Smoking cessation and bupropion: anxiety and depression as predictors of therapeutic efficacy]. ( Carreras, JM; Coll, F; Lores, L; Quesada, M; Sampablo Lauro, I; Sánchez Agudo, L, 2002) |
| " In conclusion, chronic administration of bupropion (2 and 5 mg/kg) exhibited a significant protection against triazolam withdrawal-induced anxiety and hyperlocomotor activity in mice." | 5.33 | Reversal of triazolam tolerance and withdrawal-induced hyperlocomotor activity and anxiety by bupropion in mice. ( Joshi, D; Kulkarni, SK; Naidu, PS; Singh, A, 2005) |
| " This study explored whether anxiety predicts suicidal ideation in depressed individuals treated with paroxetine or bupropion." | 5.27 | Effects of anxiety on suicidal ideation: exploratory analysis of a paroxetine versus bupropion randomized trial. ( Burke, AK; Chaudhury, SR; Ellis, SP; Grunebaum, MF; Keilp, JG; Mann, JJ; Marver, JE; Metts, AV; Oquendo, MA; Parris, MS, 2018) |
| "We tested the efficacy of bupropion in the treatment of persons with pathological gambling (PG)." | 5.12 | Bupropion in the treatment of pathological gambling: a randomized, double-blind, placebo-controlled, flexible-dose study. ( Allen, J; Argo, T; Arndt, S; Black, DW; Coryell, WH; Forbush, KT; Perry, P; Shaw, MC, 2007) |
| "Our objective was to determine if pretreatment anxiety levels were associated with preferential response to bupropion sustained release (n = 122) or sertraline (n = 126) during a 16-week randomized acute phase treatment study." | 5.09 | Response in relation to baseline anxiety levels in major depressive disorder treated with bupropion sustained release or sertraline. ( Ascher, JA; Batey, SR; Bolden-Watson, C; Carmody, TJ; Donahue, RM; Houser, TL; Metz, A; Rush, AJ; Trivedi, MH, 2001) |
| "The goal of this work was to compare the efficacy of the norepinephrine-dopamine reuptake inhibitor bupropion with the selective serotonin reuptake inhibitors (SSRIs) in the treatment of anxiety symptoms in major depressive disorder (MDD)." | 4.84 | Efficacy of bupropion and the selective serotonin reuptake inhibitors in the treatment of anxiety symptoms in major depressive disorder: a meta-analysis of individual patient data from 10 double-blind, randomized clinical trials. ( Alpert, JE; Goodale, EP; Krishen, A; Papakostas, GI; Seifert, CA; Trivedi, MH; Tucker, VL, 2008) |
| "The aim of this study was to assess the effects of the antidepressant bupropion on anxiety and novelty-seeking in adolescent mice of different ages and adults." | 3.79 | Bupropion induced changes in exploratory and anxiety-like behaviour in NMRI male mice depends on the age. ( Carrasco, MC; Redolat, R; Vidal, J, 2013) |
| "These results demonstrated that similar neural mechanisms were involved in the regulation of nicotine and D-amphetamine anxiety-like behaviour in mice." | 3.75 | Effects of co-administration of bupropion and nicotine or D-amphetamine on the elevated plus maze test in mice. ( Biala, G; Kruk, M, 2009) |
| " Anxiety levels, which are greater in the first few weeks after cessation, do not explain weight variation, which is more related to the metabolic effects of nicotine rather than to psychological variables." | 3.74 | [Weight gain and anxiety levels in recent ex-smokers]. ( Beamonte, A; Gargallo, P; Jiménez-Muro, A; Marqueta, A; Nerín, I, 2007) |
| "Evaluate acute effects of bupropion on locomotor activity, isolation-induced aggression, hole-board and elevated plus-maze tests in OF1 male mice." | 3.73 | Bupropion effects on aggressiveness and anxiety in OF1 male mice. ( Carrasco, MC; Gómez, MC; Redolat, R; Vicens, P, 2005) |
| "Bupropion attenuates some symptoms of nicotine abstinence, although its effects on anxiety are unclear." | 3.72 | Effects of acute administration of bupropion on behavior in the elevated plus-maze test by NMRI mice. ( Carrasco, MC; Redolat, R; Vicens, P; Vidal, J, 2004) |
| "Flexibly dosed triple-combination pharmacotherapy for up to 6 months was more effective than standard-duration nicotine patch therapy for outpatient smokers with medical illnesses." | 2.74 | Triple-combination pharmacotherapy for medically ill smokers: a randomized trial. ( Bover, MT; Carson, JL; Foulds, J; Greenhaus, S; Hoover, DR; Schmelzer, AC; Steinberg, MB, 2009) |
| "Bupropion XL was superior to placebo at endpoint in reducing the IDS-IVR-30 total score (p = ." | 2.72 | Extended-release bupropion for patients with major depressive disorder presenting with symptoms of reduced energy, pleasure, and interest: findings from a randomized, double-blind, placebo-controlled study. ( Hampton, KD; Jefferson, JW; Krishen, A; Modell, JG; Nelson, JC; Rush, AJ; VanMeter, SA; Wightman, DS, 2006) |
| "The small number of studies that examined side effects within fixed-dose trials may have limited the power to examine the association between medication dosing and risk of headache." | 2.58 | Meta-analysis: Second generation antidepressants and headache. ( Bloch, MH; Olten, B; Telang, S; Walton, C, 2018) |
| "Mirtazapine has moderate efficacy for depression if sedation and weight gain side effects are tolerated and some small support for use in nausea and vomiting." | 2.53 | Empirically Supported Use of Psychiatric Medications in Adolescents and Adults with IBD. ( Bielefeldt, K; Szigethy, E; Thorkelson, G, 2016) |
| "Fatigue was assessed with the Modified Fatigue Impact Scale (MFIS)." | 1.39 | Reward responsiveness and fatigue in multiple sclerosis. ( Capello, E; Krueger, F; Mancardi, G; Pardini, M; Uccelli, A, 2013) |
| "Bupropion is an atypical antidepressant that also has utility as a smoking cessation aid." | 1.36 | Effects of hydroxymetabolites of bupropion on nicotine dependence behavior in mice. ( Blough, BE; Carroll, FI; Damaj, MI; Grabus, SD; King, LS; Lukas, RJ; Navarro, HA; Vann, RE; Warner, JA; Wiley, JL, 2010) |
| "Bupropion, administered alone or combined with nicotine, is presently used to treat nicotine dependence." | 1.35 | Effects of bupropion, alone or coadministered with nicotine, on social behavior in mice. ( Carrasco, C; Gómez, C; Redolat, R, 2008) |
| " In conclusion, chronic administration of bupropion (2 and 5 mg/kg) exhibited a significant protection against triazolam withdrawal-induced anxiety and hyperlocomotor activity in mice." | 1.33 | Reversal of triazolam tolerance and withdrawal-induced hyperlocomotor activity and anxiety by bupropion in mice. ( Joshi, D; Kulkarni, SK; Naidu, PS; Singh, A, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (2.94) | 18.2507 |
| 2000's | 22 (64.71) | 29.6817 |
| 2010's | 10 (29.41) | 24.3611 |
| 2020's | 1 (2.94) | 2.80 |
| Authors | Studies |
|---|---|
| Cândido, RCF | 1 |
| Menezes de Padua, CA | 1 |
| Golder, S | 1 |
| Junqueira, DR | 1 |
| Gómez, C | 2 |
| Redolat, R | 5 |
| Carrasco, C | 2 |
| Telang, S | 1 |
| Walton, C | 1 |
| Olten, B | 1 |
| Bloch, MH | 1 |
| Parris, MS | 1 |
| Marver, JE | 1 |
| Chaudhury, SR | 1 |
| Ellis, SP | 1 |
| Metts, AV | 1 |
| Keilp, JG | 1 |
| Burke, AK | 1 |
| Oquendo, MA | 1 |
| Mann, JJ | 1 |
| Grunebaum, MF | 1 |
| Gilbert, DG | 1 |
| Rabinovich, NE | 1 |
| Gilbert-Matuskowitz, EA | 1 |
| Klein, KP | 1 |
| Pergadia, ML | 1 |
| Carrasco, MC | 3 |
| Vidal, J | 2 |
| Barsevick, AM | 1 |
| Irwin, MR | 1 |
| Hinds, P | 1 |
| Miller, A | 1 |
| Berger, A | 1 |
| Jacobsen, P | 1 |
| Ancoli-Israel, S | 1 |
| Reeve, BB | 1 |
| Mustian, K | 1 |
| O'Mara, A | 1 |
| Lai, JS | 1 |
| Fisch, M | 1 |
| Cella, D | 1 |
| Thorkelson, G | 1 |
| Bielefeldt, K | 1 |
| Szigethy, E | 1 |
| Iñiguez, SD | 1 |
| Warren, BL | 1 |
| Parise, EM | 1 |
| Alcantara, LF | 1 |
| Schuh, B | 1 |
| Maffeo, ML | 1 |
| Manojlovic, Z | 1 |
| Bolaños-Guzmán, CA | 1 |
| Biala, G | 1 |
| Kruk, M | 1 |
| Steinberg, MB | 1 |
| Greenhaus, S | 1 |
| Schmelzer, AC | 1 |
| Bover, MT | 1 |
| Foulds, J | 1 |
| Hoover, DR | 1 |
| Carson, JL | 1 |
| Damaj, MI | 1 |
| Grabus, SD | 1 |
| Navarro, HA | 1 |
| Vann, RE | 1 |
| Warner, JA | 1 |
| King, LS | 1 |
| Wiley, JL | 1 |
| Blough, BE | 1 |
| Lukas, RJ | 1 |
| Carroll, FI | 1 |
| Mahesh, R | 1 |
| Pandey, DK | 1 |
| Katiyar, S | 1 |
| Kukade, G | 1 |
| Viyogi, S | 1 |
| Rudra, A | 1 |
| Pardini, M | 1 |
| Capello, E | 1 |
| Krueger, F | 1 |
| Mancardi, G | 1 |
| Uccelli, A | 1 |
| Sampablo Lauro, I | 1 |
| Carreras, JM | 1 |
| Lores, L | 1 |
| Quesada, M | 1 |
| Coll, F | 1 |
| Sánchez Agudo, L | 1 |
| Fakhfakh, R | 1 |
| Hsairi, M | 1 |
| Gharbi, L | 1 |
| Aouina, H | 1 |
| Bouacha, H | 1 |
| Achour, N | 1 |
| Gómez, MC | 1 |
| Vicens, P | 2 |
| Malik, AR | 1 |
| Wolf, PK | 1 |
| Ravasia, S | 1 |
| Clark, MM | 1 |
| Hays, JT | 1 |
| Vickers, KS | 1 |
| Patten, CA | 1 |
| Croghan, IT | 1 |
| Berg, E | 1 |
| Wadewitz, S | 1 |
| Schwartz, S | 1 |
| Decker, PA | 1 |
| Offord, KP | 1 |
| Squires, RW | 1 |
| Hurt, RD | 1 |
| Joshi, D | 1 |
| Naidu, PS | 1 |
| Singh, A | 1 |
| Kulkarni, SK | 1 |
| Hsiao, SY | 1 |
| Cherng, CF | 2 |
| Yang, YK | 1 |
| Yeh, TL | 1 |
| Yu, L | 2 |
| Csoka, AB | 1 |
| Shipko, S | 1 |
| Jefferson, JW | 1 |
| Rush, AJ | 2 |
| Nelson, JC | 1 |
| VanMeter, SA | 1 |
| Krishen, A | 2 |
| Hampton, KD | 1 |
| Wightman, DS | 1 |
| Modell, JG | 1 |
| Selby, P | 1 |
| Nerín, I | 1 |
| Beamonte, A | 1 |
| Gargallo, P | 1 |
| Jiménez-Muro, A | 1 |
| Marqueta, A | 1 |
| Black, DW | 1 |
| Arndt, S | 1 |
| Coryell, WH | 1 |
| Argo, T | 1 |
| Forbush, KT | 1 |
| Shaw, MC | 1 |
| Perry, P | 1 |
| Allen, J | 1 |
| Su, SW | 1 |
| Lin, YC | 1 |
| Papakostas, GI | 1 |
| Trivedi, MH | 2 |
| Alpert, JE | 1 |
| Seifert, CA | 1 |
| Goodale, EP | 1 |
| Tucker, VL | 1 |
| Aylwin, S | 1 |
| Al-Zaman, Y | 1 |
| Carmody, TJ | 1 |
| Donahue, RM | 1 |
| Houser, TL | 1 |
| Bolden-Watson, C | 1 |
| Batey, SR | 1 |
| Ascher, JA | 1 |
| Metz, A | 1 |
| Emmanuel, NP | 1 |
| Lydiard, RB | 1 |
| Ballenger, JC | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Clinical and Neuropsychological Validity of Attention-Deficit Hyperactivity Disorder in Adulthood[NCT00550667] | 1,120 participants (Actual) | Observational | 2007-10-01 | Completed | |||
| NRT & Bupropion Mechanisms of Effectiveness in Smokers: Phase IV Trial[NCT01048944] | Phase 4 | 197 participants (Actual) | Interventional | 2005-06-30 | Completed | ||
| Feasibility Study of a Hypnosis Intervention and a Cognitive Behavioral Therapy Intervention to Reduce Fatigue in Patients Undergoing Chemotherapy for Metastatic Colorectal Cancer[NCT04999306] | 60 participants (Anticipated) | Interventional | 2023-05-17 | Recruiting | |||
| Effect of Resistance Training Variable Manipulation (Intensity and Volume) on Body Composition, Fatigability and Functional Capacity in Postmenopausal Breast Cancer Survivors.[NCT03644329] | 80 participants (Anticipated) | Interventional | 2018-05-13 | Recruiting | |||
| Flexibly-Dosed Combination Pharmacotherapy Versus Standard-Dosed Nicotine Patch Alone for Smokers With Medical Illness[NCT00770666] | Phase 4 | 127 participants (Actual) | Interventional | 2005-09-30 | Completed | ||
| An 8 Week, Multicenter, Randomized, Double-blind, Placebo Controlled Comparison of the Efficacy of Extended Release Bupropion Hydrochloride and Placebo in the Treatment of Adult Outpatients With Major Depressive Disorder With Lethargic Symptoms[NCT00064467] | Phase 3 | 268 participants | Interventional | 2003-06-30 | Completed | ||
| Bupropion Versus Placebo in the Treatment of Pathological Gambling[NCT00055393] | 80 participants (Actual) | Interventional | 2002-07-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Brain-wave activity (EEG) was assessed using electrodes on the subject's scalp, the outputs of which were and quantified by a commercial brain wave machine. EEG was collected at frontal (e.g., Fz) and parietal (e.g., Pz) electrodes while subjects relaxed. EEG was analyzed using computer programs that measured slow-frequency EEG waves known as delta (1.5-4.5 cycles/second [cps]), theta-1 (4.5-6.0 cps), theta-2 (6.0-7.7 cps), and alpha-1 (7.8-10.0 cps), and higher frequency waves. Generally, delta, alpha-1 and theta waves reflect deactivation of the brain activity, while higher frequency waves reflect greater brain activation. Brain activity was quantified as the natural log of EEG power [microvolts squared] as determined by the fast Fourier mathematical algorithm. Days post quit were components of Time. The primary focus was on changes in the individual subject's log theta-1, theta-2, and alpha-1 power at post-quit points in time minus the log values at the pre-quite baseline. (NCT01048944)
Timeframe: Mean EEG power [microvolts squared] from at baseline, 3, 24, 45, and 66 days post-quit
| Intervention | Change in log EEG [microvolts squared] (Mean) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Day-3 Change in log Theta-1 EEG Power Fz | Day-24 Change in log Theta-1 EEG Power Fz | Day-45 Change in log Theta-1 Power Fz | Day-66 Change in log Theta-1 EEG Power Fz | Day-3 Change in log Theta-2 Power Fz | Day-24 Change in log Theta-2 Power Fz | Day-45 Change in log Theta-2 Power Fz | Day-66 Change in log Theta-2 Power Fz | Day-3 Change in log Alpha-1 Power Pz | Day-24 Change in log Alpha-1 Power Pz | Day 45 Change in log Alpha-1 Power Pz | Day 66 Change in log Alpha-1 Power Pz | |
| Bupropion SR | .224 | .198 | .249 | .407 | .088 | .150 | .248 | .502 | .155 | .301 | .261 | .459 |
| Delayed-quit Control | -.094 | -.060 | -.032 | -.026 | -.070 | -.042 | .054 | .001 | -.004 | -.001 | .021 | .017 |
| Nicotine Patch | .055 | .194 | .232 | .431 | .062 | .251 | .319 | .504 | -.023 | .139 | .292 | .339 |
| Placebo Patch and Placebo Pill | .234 | .258 | .161 | .184 | .249 | .278 | .278 | .205 | .184 | .276 | .259 | .292 |
"Changes in log from baseline in the widely used Shiffman-Jarvik Withdrawal craving and psychological symptom scores through 66 days of abstinence. Post-quit changes were assessed at days 3, 24, 45, and 66 of abstinence. The maximal range of value raw for craving is from 5 = (no craving) to 47 (maximally strong craving), while that for psychological symptoms is from 5 (no symptoms) to 60 (maximally intense symptoms of across multiple symptoms). Because the subtraction of logs is equivalent to the ratio of the two scores, a difference in logs (base 10) with a value of 1 is equal to an increase by a factor of 10, while a value of 0 is no change, and values of less than 0 are decreases below baseline values." (NCT01048944)
Timeframe: Changes in log withdrawal symptoms from baseline through 66 days of abstinence
| Intervention | log (base 10) units on a scale (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Day-3 Change in log Shiffman Craving | Day-24 Change in log Shiffman Craving | Day-45 Change in log Shiffman Craving | Day-66 Change in log Shiffman Craving | Day-3 Change in log Shiffman Psych Withdrawal | Day-24 Change in log Shiffman Psych W | Day-45 Change in log Shiffman Psych Withdrawal | Day-66 Change in log Shiffman Psych Withdrawal | |
| Bupropion SR | .045 | -.199 | -.201 | -.230 | .210 | .102 | .063 | .032 |
| Delayed-quit Control | -.045 | -.059 | -.043 | -.075 | .016 | -.025 | -.017 | -.012 |
| Nicotine Patch | -.006 | -.187 | -.273 | -.236 | .089 | .065 | .008 | .068 |
| Placebo Patch and Placebo Pill | .094 | -.045 | -.132 | -.205 | .172 | .076 | .039 | .029 |
6 reviews available for bupropion and Anxiety
| Article | Year |
|---|---|
Immediate-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults.
Topics: Adult; Antidepressive Agents, Second-Generation; Anxiety; Attention Deficit Disorder with Hyperactiv | 2021 |
Meta-analysis: Second generation antidepressants and headache.
Topics: Adult; Antidepressive Agents, Second-Generation; Anxiety; Bupropion; Citalopram; Depression; Double- | 2018 |
Empirically Supported Use of Psychiatric Medications in Adolescents and Adults with IBD.
Topics: Adolescent; Adult; Affect; Anti-Anxiety Agents; Antidepressive Agents, Tricyclic; Anxiety; Bupropion | 2016 |
[Treatment of tobacco dependence: brief and intensive clinical intervention].
Topics: Anxiety; Bupropion; Cognitive Behavioral Therapy; Depression; Dopamine Uptake Inhibitors; Ganglionic | 2004 |
Efficacy of bupropion and the selective serotonin reuptake inhibitors in the treatment of anxiety symptoms in major depressive disorder: a meta-analysis of individual patient data from 10 double-blind, randomized clinical trials.
Topics: Adult; Antidepressive Agents, Second-Generation; Anxiety; Bupropion; Depressive Disorder, Major; Dou | 2008 |
Emerging concepts in the medical and surgical treatment of obesity.
Topics: Adipose Tissue; Amyloid; Anticonvulsants; Antidepressive Agents; Anxiety; Appetite Regulation; Baria | 2008 |
7 trials available for bupropion and Anxiety
| Article | Year |
|---|---|
Effects of anxiety on suicidal ideation: exploratory analysis of a paroxetine versus bupropion randomized trial.
Topics: Adult; Antidepressive Agents, Second-Generation; Anxiety; Bupropion; Delayed-Action Preparations; De | 2018 |
Smoking abstinence symptoms across 67 days compared with randomized controls-Moderation by nicotine replacement therapy, bupropion, and negative-affect traits.
Topics: Administration, Cutaneous; Adult; Anxiety; Behavior Therapy; Bupropion; Cigarette Smoking; Craving; | 2019 |
Triple-combination pharmacotherapy for medically ill smokers: a randomized trial.
Topics: Administration, Cutaneous; Administration, Inhalation; Adolescent; Adult; Aged; Anxiety; Bupropion; | 2009 |
Body image treatment for weight concerned smokers: a pilot study.
Topics: Adult; Antidepressive Agents, Second-Generation; Anxiety; Body Image; Body Weight; Bupropion; Cognit | 2005 |
Extended-release bupropion for patients with major depressive disorder presenting with symptoms of reduced energy, pleasure, and interest: findings from a randomized, double-blind, placebo-controlled study.
Topics: 4-Aminopyridine; Adult; Aged; Antidepressive Agents, Second-Generation; Anxiety; Bupropion; Depressi | 2006 |
Bupropion in the treatment of pathological gambling: a randomized, double-blind, placebo-controlled, flexible-dose study.
Topics: Adult; Antidepressive Agents, Second-Generation; Anxiety; Bupropion; Diagnostic and Statistical Manu | 2007 |
Response in relation to baseline anxiety levels in major depressive disorder treated with bupropion sustained release or sertraline.
Topics: Adult; Aged; Anxiety; Bupropion; Depressive Disorder, Major; Dopamine Uptake Inhibitors; Female; Hum | 2001 |
21 other studies available for bupropion and Anxiety
| Article | Year |
|---|---|
Bupropion induces social anxiety in adolescent mice: Influence of housing conditions.
Topics: Animals; Antidepressive Agents, Second-Generation; Anxiety; Behavior, Animal; Bupropion; Housing, An | 2017 |
Bupropion induced changes in exploratory and anxiety-like behaviour in NMRI male mice depends on the age.
Topics: Aging; Animals; Antidepressive Agents, Second-Generation; Anxiety; Bupropion; Dose-Response Relation | 2013 |
Recommendations for high-priority research on cancer-related fatigue in children and adults.
Topics: Adult; Anxiety; Benzhydryl Compounds; Bupropion; Central Nervous System Stimulants; Child; Clinical | 2013 |
Recommendations for high-priority research on cancer-related fatigue in children and adults.
Topics: Adult; Anxiety; Benzhydryl Compounds; Bupropion; Central Nervous System Stimulants; Child; Clinical | 2013 |
Recommendations for high-priority research on cancer-related fatigue in children and adults.
Topics: Adult; Anxiety; Benzhydryl Compounds; Bupropion; Central Nervous System Stimulants; Child; Clinical | 2013 |
Recommendations for high-priority research on cancer-related fatigue in children and adults.
Topics: Adult; Anxiety; Benzhydryl Compounds; Bupropion; Central Nervous System Stimulants; Child; Clinical | 2013 |
Nicotine exposure during adolescence induces a depression-like state in adulthood.
Topics: Aging; Animals; Antidepressive Agents, Second-Generation; Anxiety; Bupropion; Cholinergic Agents; De | 2009 |
Effects of co-administration of bupropion and nicotine or D-amphetamine on the elevated plus maze test in mice.
Topics: Animals; Animals, Newborn; Antidepressive Agents; Anxiety; Bupropion; Dextroamphetamine; Dose-Respon | 2009 |
Effects of hydroxymetabolites of bupropion on nicotine dependence behavior in mice.
Topics: Animals; Anxiety; Behavior, Animal; Bupropion; Conditioning, Operant; Discrimination Learning; Discr | 2010 |
Effect of anti-depressants on neuro-behavioural consequences following impact accelerated traumatic brain injury in rats.
Topics: Acceleration; Amitriptyline; Animals; Antidepressive Agents; Anxiety; Behavior, Animal; Brain Injuri | 2010 |
Reward responsiveness and fatigue in multiple sclerosis.
Topics: Adult; Anxiety; Attention; Bupropion; Citalopram; Cognition; Depression; Disability Evaluation; Diso | 2013 |
[Smoking cessation and bupropion: anxiety and depression as predictors of therapeutic efficacy].
Topics: Adolescent; Adult; Aged; Antidepressive Agents, Second-Generation; Anxiety; Bupropion; Depression; F | 2002 |
Bupropion effects on aggressiveness and anxiety in OF1 male mice.
Topics: Aggression; Animals; Antidepressive Agents, Second-Generation; Anxiety; Bupropion; Dose-Response Rel | 2005 |
Drugs vs. talk therapy: 3,079 readers rate their care for depression and anxiety.
Topics: Antidepressive Agents; Anxiety; Anxiety Disorders; Bupropion; Citalopram; Cyclohexanols; Depression; | 2004 |
Effects of acute administration of bupropion on behavior in the elevated plus-maze test by NMRI mice.
Topics: Animals; Antidepressive Agents, Second-Generation; Anxiety; Behavior, Animal; Bupropion; Dose-Respon | 2004 |
Recurrent paroxetine-induced hyponatremia.
Topics: Aged; Anti-Anxiety Agents; Antidepressive Agents, Second-Generation; Anxiety; Bupropion; Female; Hum | 2004 |
Reversal of triazolam tolerance and withdrawal-induced hyperlocomotor activity and anxiety by bupropion in mice.
Topics: Animals; Anxiety; Bupropion; Dopamine; Drug Tolerance; Female; Male; Mice; Motor Activity; Norepinep | 2005 |
Prenatal bupropion exposure enhances the cocaine reward and stress susceptibility in adult mice.
Topics: Animals; Antidepressive Agents, Second-Generation; Anxiety; Bupropion; Citalopram; Cocaine; Conditio | 2005 |
Persistent sexual side effects after SSRI discontinuation.
Topics: Adult; Androgens; Anxiety; Bupropion; Cabergoline; Citalopram; Depressive Disorder; Dopamine Agonist | 2006 |
Psychopharmacology of smoking cessation in patients with mental illness.
Topics: Antidepressive Agents, Second-Generation; Anxiety; Arousal; Bupropion; Citalopram; Depression; Depre | 2006 |
[Weight gain and anxiety levels in recent ex-smokers].
Topics: Adult; Anxiety; Basal Metabolism; Breath Tests; Bupropion; Carbon Monoxide; Chewing Gum; Feeding Beh | 2007 |
Prenatal exposure of bupropion may enhance agitation, anxiety responses, and sensitivity to cocaine effects in adult mice.
Topics: Aging; Animals; Antidepressive Agents, Second-Generation; Anxiety; Bupropion; Cocaine; Dose-Response | 2007 |
Effects of bupropion, alone or coadministered with nicotine, on social behavior in mice.
Topics: Aggression; Animals; Anxiety; Behavior, Animal; Bupropion; Dopamine Uptake Inhibitors; Drug Administ | 2008 |
Treatment of social phobia with bupropion.
Topics: Adult; Antidepressive Agents; Anxiety; Bupropion; Female; Humans; Phobic Disorders; Social Behavior | 1991 |